The stock of Nektar Therapeutics (NASDAQ:NKTR) last traded at $0.52, down -1.71% from the previous session.
Data from the available sources indicates that Nektar Therapeutics (NASDAQ:NKTR) is covered by 8 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.75, we find $1.75. Given the previous closing price of $0.53, this indicates a potential upside of 230.19 percent. NKTR stock price is now -14.39% away from the 50-day moving average and -72.42% away from the 200-day moving average. The market capitalization of the company currently stands at $96.47M.
In total, 6 analysts have assigned it a hold rating, and 0 have given it a buy rating. Brokers who have rated the stock have averaged $2.38 as their price target over the next twelve months.
With the price target reduced from $1.50 to $1, Jefferies Upgraded its rating from Underperform to Hold for Nektar Therapeutics (NASDAQ: NKTR).
In other news, WHITFIELD ROY A, Director sold 30,000 shares of the company’s stock on Jun 14. The stock was sold for $17,100 at an average price of $0.57. Upon completion of the transaction, the Director now directly owns 216,250 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President & CEO ROBIN HOWARD W sold 20,361 shares of the business’s stock. A total of $14,660 was realized by selling the stock at an average price of $0.72. This leaves the insider owning 939,797 shares of the company worth $0.49 million. Insiders disposed of 325,608 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NKTR stock. A new stake in Nektar Therapeutics shares was purchased by DEEP TRACK CAPITAL, LP during the first quarter worth $900,000. ORBIMED ADVISORS LLC invested $534,000 in shares of NKTR during the first quarter. In the first quarter, DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT acquired a new stake in Nektar Therapeutics valued at approximately $149,000. CAPTION MANAGEMENT, LLC acquired a new stake in NKTR for approximately $91,000. WALLEYE TRADING LLC purchased a new stake in NKTR valued at around $43,000 in the second quarter.
With an opening price of $0.5300 on Tuesday morning, Nektar Therapeutics (NASDAQ: NKTR) set off the trading day. During the past 12 months, Nektar Therapeutics has had a low of $0.52 and a high of $5.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.20, and a quick ratio of 7.90. The fifty day moving average price for NKTR is $0.5984 and a two-hundred day moving average price translates $1.8574 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.73, missing analysts’ expectations of -$0.25 by -0.48. This compares to -$0.49 EPS in the same period last year. The company reported revenue of $21.59 million for the quarter, compared to $24.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.0 percent. For the current quarter, analysts expect NKTR to generate $21.79M in revenue.
Nektar Therapeutics(NKTR) Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
